TRANSFUSION–VOLUME 30 (1990)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parenthesis following the page number indicates that the subject entry appeared in letters to the editor; an "E" in parenthesis indicates the subject was discussed in an editorial.

In Volume 30 (1990), Number One (January) contains pages 1-96; Number Two (February), pages 97-192; Number Three (March-April), pages 193-288; Number Four (May), pages 289-383; Number Five (June), pages 384-479; Number Six (July-August), pages 480-575; Number Seven (September), pages 576-670; Number Eight (October), pages 671-767; and Number Nine (November-December), pages 768-865.

A

AABB, see American Association of Blood Banks
ABO blood group system ..... 142, 671(E), 766(L)
Abstracts, National Hemophilia Foundation ..... 195(E), 277
Acquired immune deficiency syndrome (AIDS)
  effect on preoperative autologous blood donation 418
  case lists, use in lookback procedures 214
  RBC use in 133
  transfusion-associated 214
Adenosine triphosphate (ATP) levels in RBC storage 150, 339, 828
Adenylate kinase, detection of platelet lysis 536
Administration
  costs of
    ALT donor screening tests 363, 368
    antigen-matching of RBCs ..... 482(E), 532
    autologous control versus IAT in compatibility testing 503
  effect of public opinion on donor screening tests 363, 368
  of informed consent doctrine 460
  prevention of transfusion-associated deaths ..... 579(E), 583
  workload, effect of PEG-IAT ..... 318, 767(L)
AIDS, see acquired immune deficiency syndrome
AIDS-related complex (ARC), RBC usage in 133
AIHA, see autoimmune hemolytic anemia
Alanine, RBC additive 339
Alanine aminotransferase (ALT)
  costs of testing 363, 368
  correlation with HCV antibody ..... 382(L), 374, 776
  efficacy of ..... 4(E), 363, 368
  reduction of NANB posttransfusion hepatitis 363, 368
  standardization of cutoff values in ..... 76(L)
Alloimmunization
  prevention by antigen-matching of RBCs ..... 482(E), 532
  reduction by UVB irradiation 401
  selection of platelets in 314
  to platelet-specific antigens in glycoproteins 622
Alpha-granule release, in platelet storage 639
ALT, see alanine aminotransferase
AMCA, see tranexamic acid
American Association of Blood Banks (AABB)
  committee reports ..... 669(L)
  purchase of journal **TRANSFUSION** ..... 5(E)
  standards
    bone marrow processing and storage, development of ..... 571, 574(L)
    compatibility testing 39
    irradiation of blood from first-degree family members ..... 101(E), 849, 850
    prenatal and perinatal testing ..... 175, 669(L)
    reissue of RBCs 58
Ammonium chloride, effect on RBC preservation 150
Amniocentesis, risk of FMH 344
Anemia
  acute ..... 1(E), 11
  hemolytic
    associated with
      cephalosporins 263
      IVIG 436
    autoimmune 261, 714, 738
    cefotaxime-induced 263
    cold, autoimmune 267, 838
  in AIDS and ARC patients 133
  in donors 239
  in fetus 344
  in infants due to FMH 344
  in Kawasaki disease 738
Animal model
  accelerated erythropoeisis and autologous donation 295
  transfusion and metastases 188
  transfusion trigger ..... 1(E), 11
Anti-HBc, see hepatits B virus core antibody
Antibody, general
  anti-IgA-mediated transfusion reaction 322
  association of RBC antibodies and HLA markers ..... 15, 764(L)
  autoantibody in normal donors and patients with AIHA 411
  detection
    autologous control versus IAT 503
    of drug-dependent platelet-reactive antibodies 694
    of in vivo activity 439
    of platelet antibodies in the presence of HLA antibodies 622
    with PEG 318
  drug absorption versus immune-complex mechanism 263
  effect of citrate in reagent preservatives 267
  formation in LDL cholesterol apheresis 327
  IgG subclasses in IVIG 436
  incidence after multiple RBC transfusions 532
  in IVIG 436
  loss of antigen 46
  monoclonal
    characterization of RBC antigen epitopes 230
    detection of
      platelet activation 20
      Rh-related glycoproteins 222
    evaluation of RBC autoantibodies 390, 411, 495
    screening agent for anti-e 226
  quantitation of RBC-bound autoantibody in AIHA ..... 576(E), 617
  RBC antibody formation and HLA markers ..... 15, 764(L)
  role of MHC in RBC antibody formation ..... 15, 764(L)
  thimerosal-associated antibody ..... 667(L)
  WBC and febrile, nonhemolytic transfusion reactions 733
Antibody, specific
  anti-A 436
  anti-B 436
  anti-D ..... 15, 764(L)
  anti-E 532
  anti-e-like 226
  anti-GP Ib/IX 622
  anti-GP IIb-IIIa 622
  anti-idiotypic 495, 651
  anti-IgA 322
  anti-IgG1 κ with Pr_s specificity 838
  anti-Jk3 46
  anti-Ju 261
  anti-K 532
  anti-Lu6 258
  anti-NB2 42
  anti-$P1^{A1}$ 433
  anti-Pr_{1d} 267
  anti-Pr_2 495
  anti-Sc1 439
  MB-2D10 for Rh-related glycoproteins 222
Antifibrinolytic agents, pharmacology and use 541
Anti-HBc, see hepatitis B virus core antibody
Anti-idiotypic antibodies 495, 651
Antigen, general

TRANSFUSION–VOLUME 30 (1990)
Subject Index

In the subject index, the page number refers to the first page of the communication in which the subject is addressed rather than to the specific page on which the referenced key words can be found. An "L" in parenthesis following the page number indicates that the subject entry appeared in letters to the editor; an "E" in parenthesis indicates the subject was discussed in an editorial.

In Volume 30 (1990), Number One (January) contains pages 1-96; Number Two (February), pages 97-192; Number Three (March-April), pages 193-288; Number Four (May), pages 289-383; Number Five (June), pages 384-479; Number Six (July-August), pages 480-575; Number Seven (September), pages 576-670; Number Eight (October), pages 671-767; and Number Nine (November-December), pages 768-865.

A

AABB, see American Association of Blood Banks
ABO blood group system ..... 142, 671(E), 766(L)
Abstracts, National Hemophilia Foundation ..... 195(E), 277
Acquired immune deficiency syndrome (AIDS)
  effect on preoperative autologous blood donation 418
  case lists, use in lookback procedures 214
  RBC use in 133
  transfusion-associated 214
Adenosine triphosphate (ATP) levels in RBC storage 150, 339, 828
Adenylate kinase, detection of platelet lysis 536
Administration
  costs of
    ALT donor screening tests 363, 368
    antigen-matching of RBCs ..... 482(E), 532
    autologous control versus IAT in compatibility testing 503
  effect of public opinion on donor screening tests 363, 368
  of informed consent doctrine 460
  prevention of transfusion-associated deaths ..... 579(E), 583
  workload, effect of PEG-IAT ..... 318, 767(L)
AIDS, see acquired immune deficiency syndrome
AIDS-related complex (ARC), RBC usage in 133
AIHA, see autoimmune hemolytic anemia
Alanine, RBC additive 339
Alanine aminotransferase (ALT)
  costs of testing 363, 368
  correlation with HCV antibody ..... 382(L), 374, 776
  efficacy of ..... 4(E), 363, 368
  reduction of NANB posttransfusion hepatitis 363, 368
  standardization of cutoff values in ..... 76(L)
Alloimmunization
  prevention by antigen-matching of RBCs ..... 482(E), 532
  reduction by UVB irradiation 401
  selection of platelets in 314
  to platelet-specific antigens in glycoproteins 622
Alpha-granule release, in platelet storage 639
ALT, see alanine aminotransferase
AMCA, see tranexamic acid
American Association of Blood Banks (AABB)
  committee reports ..... 669(L)
  purchase of journal **TRANSFUSION** ..... 5(E)
  standards
    bone marrow processing and storage, development of ..... 571, 574(L)
    compatibility testing 39
    irradiation of blood from first-degree family members ..... 101(E), 849, 850
    prenatal and perinatal testing ..... 175, 669(L)
    reissue of RBCs 58
Ammonium chloride, effect on RBC preservation 150
Amniocentesis, risk of FMH 344
Anemia
  acute ..... 1(E), 11
  hemolytic
    associated with
      cephalosporins 263
      IVIG 436
    autoimmune 261, 714, 738
    cefotaxime-induced 263
    cold, autoimmune 267, 838
  in AIDS and ARC patients 133
  in donors 239
  in fetus 344
  in infants due to FMH 344
  in Kawasaki disease 738
Animal model
  accelerated erythropoeisis and autologous donation 295
  transfusion and metastases 188
  transfusion trigger ..... 1(E), 11
Anti-HBc, see hepatits B virus core antibody
Antibody, general
  anti-IgA-mediated transfusion reaction 322
  association of RBC antibodies and HLA markers ..... 15, 764(L)
  autoantibody in normal donors and patients with AIHA 411
  detection
    autologous control versus IAT 503
    of drug-dependent platelet-reactive antibodies 694
    of in vivo activity 439
    of platelet antibodies in the presence of HLA antibodies 622
    with PEG 318
  drug absorption versus immune-complex mechanism 263
  effect of citrate in reagent preservatives 267
  formation in LDL cholesterol apheresis 327
  IgG subclasses in IVIG 436
  incidence after multiple RBC transfusions 532
  in IVIG 436
  loss of antigen 46
  monoclonal
    characterization of RBC antigen epitopes 230
    detection of
      platelet activation 20
      Rh-related glycoproteins 222
    evaluation of RBC autoantibodies 390, 411, 495
    screening agent for anti-e 226
  quantitation of RBC-bound autoantibody in AIHA ..... 576(E), 617
  RBC antibody formation and HLA markers ..... 15, 764(L)
  role of MHC in RBC antibody formation ..... 15, 764(L)
  thimerosal-associated antibody ..... 667(L)
  WBC and febrile, nonhemolytic transfusion reactions 733
Antibody, specific
  anti-A 436
  anti-B 436
  anti-D ..... 15, 764(L)
  anti-E 532
  anti-e-like 226
  anti-GP Ib/IX 622
  anti-GP IIb-IIIa 622
  anti-idiotypic 495, 651
  anti-IgA 322
  anti-IgG1 κ with Pr_s specificity 838
  anti-Jk3 46
  anti-Ju 261
  anti-K 532
  anti-Lu6 258
  anti-NB2 42
  anti-$P1^{A1}$ 433
  anti-Pr_{1d} 267
  anti-Pr_2 495
  anti-Sc1 439
  MB-2D10 for Rh-related glycoproteins 222
Antifibrinolytic agents, pharmacology and use 541
Anti-HBc, see hepatitis B virus core antibody
Anti-idiotypic antibodies 495, 651
Antigen, general

antigen-matching of RBCs ..... 482(E), 532
biochemical nature of Kell system antigens 158
crossreactivity of HLA antisera 631
effect of chloroquine treatment 126
flow cytometric studies of 236
HLA antigen phenotypes
and GVHD 850
Chippewa Indians 728
North American Indians 521
Kx protein and RBC protein function 722
molecular basis of ABO system ..... 671(E)
neutrophil-specific 848
platelet nomenclature ..... 477(L)
preservation of RBC antigens in low-ionic-strength solutions 423
typing
B(A) phenomenon 142
density-separation ..... 477(L)
in PUBS 404
with monoclonal reagents ..... 142, 766(L)
Antigen, specific
HLA antigens on
platelets 126
RBCs 126, 521
RBC
B(A) phenomenon 142
B ..... 766(L)
Bg 126
D ..... 15, 236, 764(L)
D_{el} 236
Di(a) 728
Di(b) 728
D^u 236
Jk^a 46
K 158, 722
Antiglobulin test
direct (DAT)
comparison of DAT and direct Polybrene test 838
effect of cryoglobulin in 154
gel test 109
in cold AIHA 838
in delayed hemolytic or serologic transfusion reaction 688
indirect (IAT)
effect of cryoglobulin in 154
comparison of methods
autologous control versus IAT 503
gel test 109
solid-phase 114
use of PEG ..... 318, 767(L)
Antihemophilic factor, see factor VIII
Antimicrobial drug therapy and anemia in AIDS and ARC 133
Apheresis
reactions during 327
therapeutic
collection and processing of PBSC
automated versus manual procedures 824
vena cava catheters in 511
ECPHO ..... 288(L)
removal of LDL cholesterol 327
Apoptosis, role in control of RBC production ..... 673(E)
ARC, see AIDS-related complex
Assay
ALT 363, 368
antigen-antibody detection
antibody-dependent cellular cytotoxicity assay 439
gel test 109
solid-phase test 114
CMV 659, 808
direct Polybrene test 814
drug-dependent platelet-reactive antibodies 694
flow cytometry
drug-dependent platelet-reactive antibodies 694
platelet activation 20
RBC-bound antibody quantitation 617
Rh phenotypes 236
HCV antibody 374, 759
hematocrit ..... 474, 477(L)
hemoglobin 474
HIV-1 antibody 184, 704
HIV-2 antibody 184
HTLV-I 491, 780, 783
HTLV-II 491, 780, 783
paternity testing
DNA probes and HVR 819
endonuclease shattering of hypervariable DNA 648
RFLP 552
PCR 51, 491, 704, 833
platelet
activation 20
antibody 622, 694
crossmatching 314
quantitation in WBC-depleted components ..... 117, 377, 387(E)
quantitation of RBC-bound immunoglobulin ..... 576(E), 617
syphilis ..... 773(E), 844
VZV antibody ..... 478(L)
Western blot 491
WBC
antibody detection 733
quantitation in WBC-depleted components
accuracy of methods ..... 387(E)
hemocytometer method 777
radioimmunoassay 117
ATP, see adenosine triphosphate
Audit, FFP 253
Author index 853
Author's instructions
detailed 91
letters to the Editor 78, 91
Autoimmune hemolysis 714
Autoimmune hemolytic anemia (AIHA)
blood usage in 838
cephalosporins and 263
cold with anti-IgG κ with Pr_s specificity 838
in Kawasaki disease 738
autoantibody
assessment using
anti-idiotypic antibodies 495
Polybrene 814
production in 411
prediction of severity of hemolysis ..... 576(E), 617
Autologous donations
accelerated erythropoiesis and, animal model 295
during pregnancy and safety of fetus ..... 76(L), 168, 172
effect on participation by directed donors 246
from large-volume bone marrow harvest 310
preoperative 418
reactions in 247, 710
AZT, see zidovudine

B

B(A) phenomenon 142
Bacteria
contamination
cell separator and 146
in red cells ..... 193(E), 207, 298
of blood products, death due to ..... 207, 579(E), 583
prevention of, in waterbaths ..... 667(L)
growth in red cells 58, 298, 302
Yersinia enterocolitica ..... 193(E), 207, 579(E), 583
Benzoporphyrin derivative, in viral inactivation 485
β_2-microglobulin 126
β-thalassemia, viral infections in 808
β-thromboglobulin 634
Bleeding time, correction in von Willebrand disease ..... 381(L)
Blood filters, see filters
Blood group system
ABO ..... 142, 436, 671(E), 766(L)
Diego 722
GM 722
Kell 158, 532, 722
Kidd 46
KM 728
Lutheran 258
MNSs 230
Rh ..... 15, 222, 226, 236, 532, 764(L)
Blood loss, acute ..... 1(E), 11
Blood product testing ..... 4(E), 73
Blood supply, safety of ..... 4(E), 63, 97(E), 480(E)
Blood warming 7
Blood wastage, due to 30-minute rule 58
Books received 183
Book reviews 50, 171, 225, 417, 435, 790, 832
Bone marrow

donor registry costs 138
processing and storage standards ..... 571, 574(L)
transplantation
donor registry costs 138
large-volume harvest and autologous donation 310
unrelated donors for North American Indians 521, 728
Borrelia burgdorferi 298
Borrelia duttonii ..... 380(L)
Borrelia recurrentis ..... 380(L)
Buffy coat method of platelet preparation 634

C

Cancer
and transfusion
in animal model 188
recurrence in 291
tumor stage in 291
Carbonyl iron, use in blood donors 239
Case lists, AIDS, use in lookback procedures 214
Catheters, vena cava, use in PBSC collection and transplantation 511
Cell separators
microbial challenge of 146
processing of PBSC 824
Cephalosporins and hemolytic anemia 263
Cerebral blood flow after donation 710
Cesarean section, risk of FMH 344
Children, transfusion practice in ..... 68, 581(E), 599
Chimeras, red cell 390
Chippewa Indians, bone marrow donors 728
Cholesterol, low-density, removal by apheresis 327
Chloroquine treatment, effect on antigens 126
Chromium-51, comparison of labeling methods for platelets 407
Citrate, effect on anti-Pr_{1d} 267
Citrobacter freundii, growth rate in RBCs 302
Committee reports ..... 68, 175, 271, 565, 669(L)
Compatibility testing
AABB standards 39
comparison of autologous control and IAT 503
Complement
activation in cold AIHA 838
nomenclature of ..... 478(L)
phenotype and RBC antibody formation 15
Confidential unit exclusion (CUE) ..... 444, 668(L), 707
Conversion table, SI units 79
Cord blood, testing of 175
Correction
TRANSFUSION 1990;30:58-62 103
TRANSFUSION 1989;29(suppl):48S ..... 381(L)
Cost analysis
bone marrow donor registry 138
Cost-benefit analysis
antigen-matching of RBCs ..... 482(E), 532
blood product testing 73, 363, 368
CMV, see cytomegalovirus
Cryoglobulin, interference in antiglobulin tests 154
Cryoprecipitate, FN in 799
CUE, see confidential unit exclusion
Cyclosporine 651
Cytomegalovirus (CMV)
IgG subclass response after transfusion 528
prevalence in pediatric oncology patients ..... 573(L)
risk in
β-thalassemia major 808
FFP recipients 762
transplant recipients 659

D

DDAVP, see 1-deamino-8-D-arginine vasopressin
1-deamino-8-D-arginine vasopressin (DDAVP), pharmacology and use 541
Delayed hemolytic transfusion reaction 688
Delayed serologic transfusion reaction 688
Density-gradient separation of PBSC 824
Denys, Jean Baptiste 358
Desmopressin, see 1-deamino-8-D-arginine vasopressin
Diluent (RBC) and hemolysis ..... 78(L)
2,3 diphosphoglycerate (2,3 DPG), changes during red cell storage 339, 828
2,3 DPG, see 2,3 diphosphoglycerate
DNA probes and HVR, in paternity testing 648, 819
Donath-Landsteiner test 838
Donor(s)
anemia in 239
autologous
accelerated erythropoiesis, animal model 295
effect of directed donors on participation of 246
pregnancy and ..... 76(L), 168, 172
preoperative 418
reactions in 249, 710
bone marrow
Chippewa Indians as 728
North American Indians as 521
recruitment of 138
registry, costs of 138
cerebral blood flow in 710
demographics of 444
deferral
CUE ..... 444, 668(L), 707
reduction, by second fingerstick 474
self-exclusion 444
directed
effect on autologous donor participation 246
committed donor ..... 68, 581(E), 599
for infants and children ..... 68, 581(E), 599
limited-exposure 68
patient-related ..... 68, 101(E), 581(E), 599
risk of GVHD ..... 68, 101(E), 849, 850
iron replacement in 239
limited-exposure 68
motivation theory of 444
patient-related ..... 68, 101(E), 849, 850
pregnant ..... 76(L), 168, 172
reactions 249, 710
risks from donation ..... 581(E), 599, 710
safety of
autologous donation during pregnancy ..... 76(L), 168, 172
committed-donor during donation ..... 581(E), 599
donors 63
fetus in autologous donation during pregnancy ..... 76(L), 168, 172
screening
ALT ..... 4(E), 76(L), 363, 368, 374, 382(L), 776
efficacy of ..... 4(E), 63, 73, 363, 368
HCV antibody ..... 374, 382(L), 471, 667(L), 759, 776
hemoglobin 239, 474
hepatitis B core antibody (anti-HBc) ..... 382(L), 384(E), 431
hepatitis B surface antigen ..... 4(E), 384(E), 431
HIV-1
antibody ..... 77(L), 184, 201, 491, 704
CUE ..... 444, 668(L), 707
DNA detection 704
HIV-1 antigen ..... 4(E), 73
HIV-2 184
HTLV-I/II 780, 783, 787
public opinion and ..... 4(E), 363, 368
syphilis 773, 844
transplant, prenatal identification of 682
Dosage effect in HLA phenotyping 631
Drug absorption mechanism of antibody action 263
Drug-dependent platelet-reactive antibodies 694

E

EACA, see epsilon-aminocaproic acid
ECMO, see extracorporeal membrane oxygenation
Education, physician
HCV lookback 759
use of FFP 253
Epsilon-aminocaproic acid (EACA) 541
Error
TRANSFUSION 1990;30:58-62 103
TRANSFUSION 1989;29(suppl):48S ..... 381(L)
Erythropoiesis, after autologous blood donation, animal model 295
Erythropoietin, role in RBC production ..... 673(E)
Ethics and informed consent doctrine 460
Extracorporeal immunoadsorption, removal of LDL cholesterol 327
Extracorporeal membrane oxygenation (ECMO) ..... 289(E), 307
Extracorporeal photochemotherapy (ECPHO) ..... 288(L)

F

Factor VIII (FVIII)
concentrate
preparation after 8-hour hold of whole blood 828
shortage of ..... 573(L)
use in von Willebrand disease ..... 381(L)
viral inactivation of ..... 192(L), 480(E), 591, 748
inhibitors 626, 748
production of new products 748
recombinant 748
Factor IX concentrate, use in hemophilia B during surgery 441
Fanconi anemia 682
FDA, see U.S. Food and Drug Administration
Fetus
anemia in 344
diagnosis of Fanconi anemia 682
PUBS in 104
safety of, during autologous donation in pregnancy ..... 76(L), 168, 172
transfusion in 104, 175
Fetomaternal hemorrhage (FMH) 175, 344
FFP, see fresh-frozen plasma
Fibrin glue 741
Fibronection (FN) 791, 799
Filters
comparison of 26, 34, 117
complications of use ..... 288(L)
effect on platelet function 718
reduction of HIV-1 ..... 191(L), 833
white-cell depletion ..... 26, 30, 34, 117, 288(L), 377, 387(E), 718
use in PNH ..... 479(L)
Flow cytometry 20, 236, 617, 694
FMH, see fetomaternal hemorrhage
FN, see fibronectin
Freeze-thaw procedure for HIV reduction 833
Fresh-frozen plasma (FFP)
CMV transmission risk 762
HIV transmission risk 851
transfusion practice, modification through education 253
use in ECMO ..... 289(E), 307
viral inactivation of ..... 192(L), 480(E), 591, 748
FVIII, see factor VIII

G

Gene cloning of the ABO blood group system ..... 671(E)
Glycoproteins
platelet membrane
alloimmunization to 622
changes during storage due to WBCs 333
RBC membrane, Rh-related 222
Graft-versus-host disease (GVHD)
in limited-exposure transfusion 68
in patient-related transfusion ..... 68, 101(E)
transfusion-associated ..... 68, 101(E), 849, 850
Graft-versus-leukemia effect ..... 191(L)
Granulocyte, anti-NB2 and TRALI 42
Guidelines, prenatal and perinatal immunohematology ..... 175, 669(L)
GVHD, see graft-versus-host disease

H

HCV, see hepatitis C virus
HDN, see hemolytic disease of the newborn
Healthcare workers
risk of HIV infection in ..... 382(L)
safety of 63
Hematocrit
microhematocrit, self-sealing tube ..... 477(L)
transfusion trigger ..... 1(E), 11
Hematopoietic stem cell (PBSC)
comparison of processing procedures 824
transplatation, use of vena cava catheter 511
Hemoglobin
level and transfusion trigger ..... 1(E), 11
use as red cell substitute 516
Hemolysis
autoimmune, effect of multiple immunoglobulin classes in 714
prediction of severity, in AIHA ..... 576(E), 617, 714
RBC diluent and ..... 78(L)
Hemolytic disease of the newborn (HDN)
anti-Sc1 and 439
reduction of by antigen-matching of red cells 532
serologic management of 175
severity, correlation with IgG subclass ..... 381(L)
treatment with umbilical vein transfusion 104
Hemophilia A
effect of FN in cryoprecipitate and plasma 799
FVIII usage during shortage ..... 573(L)
new products in treatment of 748
prevalence of HTLV-I/II 780
T-cell abnormalities in 799
use of
anti-inhibitor coagulant complex 626
DDAVP in 541
limited-exposure donations in 68
Hemophilia B, use of F IX or PCC during surgery 441
Hepatitis B virus (HBV)
core antibody (anti-HBc), correlation with HCV antibody ..... 382(L), 776
lookback 431
low-level carriers of ..... 384(E), 431
inactivation by TNBP 591
surface antigen testing ..... 4(E), 384(E), 431, 776
transfusion-transmitted ..... 384(E), 431
Hepatitis C virus (HCV)
antibody
correlation with
ALT levels ..... 374, 382(L), 471, 776
anti-HBc ..... 382(L), 471, 776
prevalence in
Chinese in Taiwan 471
Italy ..... 382(L)
Japan ..... 374, 667(L)
Norway 776
United States 759
use in screening for NANBH 374
lookback ..... 374, 380(L), 759
Hepatitis
non-A,non-B
ALT screening for 363, 368
inactivation of ..... 480(E)
Hexadimethrine bromide (Polybrene) 814
History of
blood transfusions 358
TRANSFUSION 768
HIV-1, see human immunodeficiency virus type 1
HIV-2, see human immunodeficiency virus type 2
HLA
antibodies, interference in detection of platelet-specific tests 622
antigens on
platelets 126
red cells 126, 521
antisera, crossreactivity of 631
phenotype
and red cell antibody formation ..... 15, 764(L)
dosage effect 631
of Chippewa Indians 728
of North American Indians 521
Human immunodeficiency virus type 1 (HIV-1)
antibody, prevalence in donors ..... 77(L), 201
antigen, tests for ..... 4(E), 73
crossreactivity with HIV-2 184
CUE donor deferral ..... 668(L), 707
DNA detection 704
inactivation ..... 480(E), 591
lookback procedures 214
reduction by
filtration ..... 191(L), 833
storage of RBCs 851
WBC-depletion 833, 851
risk of infection in healthcare staff ..... 382(L)
Human immunodeficiency virus type 2 (HIV-2)
crossreactivity with HIV-1 184
inactivation by solvent/detergent treatment ..... 192(L)
Human T-cell lymphotrophic virus type I (HTLV-I)
lookback ..... 380(L)
lymphocyte subsets in 787
seroprevalence in
hemophiliacs 780
U.S. plasma donors 780
U.S. blood donors 491, 783
Human T-cell lymphotropic virus type II (HTLV-II)
lymphocyte subsets in 787

seroprevalence in
hemophiliacs 780
U.S. plasma donors 780
U.S. blood donors 491, 783
HVR, see hypervariable region
Hypervariable region (HVR), in paternity testing 819

I

IAT, see antiglobulin test, indirect
IgA, antibody removal from platelet concentrates 322
Immune complex-mechanism of antibody action 263
Immune globulins
IgA, antibody 322
IgG
quantitation of red cell-bound ..... 579(E), 617
subclass
and autoimmune hemolysis 714
and severity of HDN ..... 381(L)
in IVIG 436
response to CMV 528
Immune hemolytic anemia, correlation of RBC-bound IgG and in vivo hemolysis ..... 576(E), 617, 714
Immune modulation and transfusion 188, 291, 644, 651
Immunohematology, prenatal and perinatal 175
Immune response, effect of transfusion 651
Immunosuppression by FN 791, 799
Indirect antiglobulin test (IAT), see antiglobulin test
Index, authors 853
Infants, transfusion practice 68
Informed consent doctrine 460
Inhibitors to FVIII 626, 748
Institute of Medicine of the National Academy of Science 63
Instructions for Authors
detailed 91
Letters to the Editor 78, 91
Intraoperative blood salvage 599
Intravenous immune globulin (IVIG) 436, 738
In utero transfusions 104
Iron deficiency in blood donors 239
Irradiation
gamma
effect on RBC potassium levels ..... 675(E), 764(L)
prevention of GVHD ..... 101(E), 849, 850
IVIG, see intravenous immune globulin

K

Kawasaki disease 738
Kell blood group system 158, 532, 722
Kidd blood group system 46
Kleihauer-Bethke procedure 344

L

Lactate dehydrogenase, detection of platelet lysis 536
Landsteiner Award lecture 390
Lectins 390
LDL cholesterol, see low-density lipoprotein cholesterol
Letters to the Editor, instructions 78, 91
Limited-exposure donations and transfusions 68
Lookback
HBV, low-level carriers 431
HCV ..... 374, 380(L), 759
HIV 214
HTLV-I ..... 380(L)
procedures, crossreference with AIDS case reports 214
Low-density lipoprotein cholesterol (LDL) 327
Lutheran blood group system 258
Lyme disease 298
Lymphocytes
reactivity, effect of FN 791, 799
role in autoantibody production 411
subpopulations in transfused patients 644
subsets in HTLV-I/II-positive donors 787

M

Major histocompatibility complex (MHC) and anti-D formation ..... 15, 764(L)
Mannitol, effect on RBC preservation 150
McLeod syndrome 158, 722
Membranes
in RBCs in McLeod syndrome 722
platelets 126, 622
RBC 126, 222
Methoxsalen ..... 288(L)
MHC, see major histocompatibility complex
Minimal-exposure transfusion ..... 581(E), 599
Monoclonal antibodies
detection of
B(A) typing phenomenon 142
HLA antigens 126
platelet activation 20
platelet membrane glycoproteins 126, 634
WBCs and platelets in WBC-depleted components 117
weak variants of A antigen 142
effect of PEG on ..... 766(L)
evaluation of RBC autoantibodies 495
purified FVIII 748
RBC antigen epitope characterization 230
use for screening for anti-e 226
MNSs blood group system 230
Motivation theory of blood donation 444
Mycobacterium avium complex and anemia in AIDS and ARC 133

N

NANBH, see non-A,non-B hepatitis
National Aeronautics and Space Administration (NASA), blood storage experiment 605
National Heart, Lung, and Blood Institute (NHLBI) ..... 97(E)
National Hemophilia Foundation (NHF), meeting abstracts ..... 195(E), 277
National Marrow Donor Program 521, 728
Needlestick injury, risk of HIV infection ..... 382(L)
Neonatal patients
clinical condition after FMH 344
transfusion practice
in ECMO ..... 289(E), 307
limited-exposure 68
minimal-exposure ..... 581(E), 599
patient-related 68
serologic testing 175, 669
small-volume red cell 565
survey of, 1985 271
use of irradiated RBCs ..... 675(E), 764(L)
NHF, see National Hemophilia Foundation
NHLBI, see National Heart, Lung, and Blood Institute
Nomenclature
complement ..... 478(L)
platelet antigens ..... 477(L)
Non-A,non-B hepatitis (NANBH)
ALT screening for 363, 368
HCV antibody screening for 374
North American Indians, bone marrow donors 521, 728

O

Operative sealant 741
Oxygen extraction ratio ..... 1(E), 11

P

Parentage testing, see paternity testing
Paroxysmal nocturnal hemoglobinuria (PNH) ..... 479(L)
Paternity testing
DNA probes and HVR in 819
endonuclease shattering of hypervariable DNA 648
use of RFLP in 552
PBSC, peripheral blood stem cells, see hematopoietic stem cells
PCC, see prothrombin complex concentrate
PCR, see polymerase chain reaction
Pediatric patients
minimal-exposure transfusion ..... 581(E), 599
prevalence of CMV antibody in ..... 573(L)
PEG, see polyethylene glycol
Percutaneous umbilical blood sampling (PUBS) 104
PEP, see phosphoenolpyruvate
Pharmacologic agents, use in bleeding disorders 541
Philosophical Transactions 358
PHP, see pyridoxalated hemoglobin-polyoxyethelene
Phosphoenolpyruvate (PEP), RBC additive 339
Plasma

FN in 799
transmission of HTLV-I/II 780
viral inactivation of ..... 192(E), 480(E), 591, 748
Plasticizers in blood bags ..... 767(L)
Platelet
activation
detection by flow cytometry and monoclonal antibodies 20
during preparation 634
antibody detection
in the presence of HLA antibodies 622
of drug-dependent antibodies 694
antigen nomenclature ..... 477(L)
concentrates
crossmatching 314
function after white cell depletion 718
HIV transmission risk 851
preparation
after 8-hour hold of whole blood 828
buffy coat method 634
of IgA-deficient 322
of WBC-depleted 34
morphology changes in 634
platelet-rich plasma method 634
storage and preservation
activation during 20
alpha-granule release in 639
comparison of storage bags 850
effect of
agitation 427, 639
37°C temperature 701
8-hour hold of whole blood 828
microgravity 605
WBCs in 333
function during 20, 333, 427, 639
lysis during 536
membrane changes in 333
metabolism in 639
morphology changes during 20, 701
thromboxane B_2 formation in 639
with discontinuation of agitation 427
UVB irradiation of 678
washing, removal of IgA 322
white cell-depleted ..... 34, 288(L), 377, 387(E), 718
drug-dependent antibodies 694
membrane components 126, 622, 634
posttransfusion recovery, effect of 37°C storage 701
selection of, in alloimmunized patients 314
survival
after 8-hour hold of whole blood 828
after WBC depletion 34, 718
chromium-51, comparison of methods 407
in splenomegaly 508
without agitation during storage 639
transfusion
reaction
anti-IgA in 322
febrile ..... 765(L)
single versus multiple donors ..... 765(L)
use in
ECMO ..... 289(E), 307
splenomegaly 508
posttransfusion purpura 433
UVB irradiation of 678
Photopheresis ..... 288(L)
Photosensitizers
benzoporphyrin derivative 485
viral inactivation by ..... 480(E), 485
PNH, paroxsymal nocturnal hemoglobinuria
Polybrene, see hexadimethrine bromide
Polyethylene glycol (PEG) ..... 318, 766(L), 767(L)
Polymerase chain reaction (PCR) 51, 491, 704, 833
Postoperative erythroderma (POE) ..... 101(E)
Posttransfusion purpura 433
Potassium, levels in irradiated RBCs ..... 675(E), 764(L)
Pregnancy
and autologous blood donation ..... 76(L), 168, 172
serologic tests in 175
Prenatal and perinatal immunohematology 175
Preoperative autologous blood donation 418
Pretransfusion compatibility testing 39
Prothrombin complex concentrate (PCP) 441
Prostacyclin 34
Pseudomonas aeruginosa, growth rate in red cells 58, 302
Public opinion and blood screening tests ..... 4(E), 363, 368
PUBS, see percutaneous umbilical blood sampling
Pyridoxalated hemoglobin-polyoxyethylene (PHP) 516

Q

Quality control, quantitation of WBCs in WBC-depleted products ..... 117, 387(E)

R

Rapid communications 775
RBC(s), see red cell(s)
Reagents
antiglobulin, neutralization by cryoglobulin 154
bovine serum albumin, comparison with PEG in IAT ..... 318, 767(L)
effect of citrate in preservative solutions on RBC antibodies 267
HLA typing sera, crossreactivity of 631
monoclonal antibodies
detection of
platelet activation 20
platelet membrane glycoproteins 634
RBC antigens in PUBS 104
WBCs in WBC-depleted components 117
effect of PEG on ..... 766(L)
PEG, routine use ..... 318, 767(L)
RBC storage and preservation medium 150, 339, 423
Recombinant FVIII 748
Red cells (RBC)
and GVHD ..... 68, 101(E), 849, 850
and immune modulation 291
antibodies
association with HLA markers ..... 15, 764(L)
incidence after transfusion 532
quantitation of 617
antigen
detection by flow cytometry 236
-matching ..... 482(E), 532
autoantibodies, evaluation of ..... 390, 411, 495, 576(E), 583, 617
bacterial contamination of ..... 193(E), 207
bacterial growth rate in 58, 302
chimeras 390
clearance of fetal cells from maternal circulation 344
compatibility testing 39
diluents and hemolysis ..... 78(L)
hemagglutination 390
HIV transmission risk 851
irradiation and plasma potassium ..... 675(E), 764(L)
membrane
abnormalities, in McLeod syndrome 158, 722
components 126
glycoproteins 222
phenotyping, B(A) phenomenon 142
plasma potassium after irradiation ..... 675(E), 764(L)
polyagglutinability 390
preparation
effect of 8-hour hold of whole blood 828
inositol hexaphosphate osmotic pulse treatment 196
preservation and storage
additives
alanine and PEP 339
ammonium chloride and mannitol solutions 150
at microgravity 605
bacterial growth rate in 58, 298, 302
changes in
ATP 150, 339, 828
2,3 DPG 339, 828
effects of
8-hour hold of whole blood 828
room-temperature exposure 302
reduction of HIV infectivity during 851
survival of *B. burgdorferi* 298
production of ..... 673(E)
reagents, storage 423
reissue of 58
serologic relationship with microbes 390
substitutes 516
survival
after preparation with

an 8-hour hold of whole blood 828
inositol hexaphosphate osmotic pluse treatment 196
after warming 7
51-Cr labeling 258
transfusion
usage in
AIDS and ARC patients 133
ECMO ..... 289(E), 307
neonatal patients ..... 271, 565, 675(E), 764(L)
PNH ..... 479(L)
limited-exposure 68
minimal-exposure ..... 581(E), 599
small-volume 565
umbilical vein 104
warming 7
washing
after irradiation ..... 675(E), 764(L)
and reduction of HIV infectivity 851
wastage due to reissue rule 58
WBC-depleted ..... 26, 30, 377, 387(E), 479(L), 851
Regulatory agency for blood components ..... 4(E), 63
Relapsing fever, transfusion-transmitted ..... 380(L)
Research opportunities in transfusion medicine ..... 97(E)
Restriction fragment length polymorphism (RFLP) 552
RFLP, see restriction fragment length polymorphism
Rh blood group system ..... 15, 222, 226, 236, 532, 764(L)
RhIG, see Rh immune globulin
Rh immune globulin (RhIG) therapy 175, 344
Risk/benefit analysis for testing of blood components 73
Risk of blood donation ..... 581(E), 599, 710

S

Safety of
blood storage bags ..... 767(L)
blood supply ..... 4(E), 63, 97(E), 480(E)
health care workers ..... 63, 382(L), 477(L)
self-sealing microhematocrit tube ..... 477(L)
Sickle cell anemia, antigen-matching of RBCs in ..... 482(E), 532
SI units, see Systeme International d'Unites
Splenomegaly, effect of platelet transfusion 508
Standards, bone marrow processing and storage ..... 571, 574(L)
Standard operating procedure, blood administration ..... 579(E), 583
Staphylococcus aureus, growth rate in red cells 302
Staphylococcus epidermidis, growth rate in red cells 302
Streptococcus faecalis, growth rate in red cells 302
Submission of
manuscripts 91
Letters to the Editor 78, 91
Survey of RBC transfusion practice, 1985 271
Syphilis 733, 775
Systeme International d'Unites ..... 6(E), 79

T

Taq, see *Thermus aquaticus*
T-cell abnormalities in hemophiliacs 799
Thalassemia, β, viral infections in 808
Thermus aquaticus 51
Thimerosal-associtated antibody ..... 667(L)
Thrombotic thrombocytopenia purpura, TRALI in 42
Thromboxane B_2, formation during platelet storage 639
TNBP, see tri(n-butylphosphate
TRALI, see transfusion-related acute lung injury
Tranexamic acid (AMCA) 541
TRANSFUSION
purchase of ..... 5(E)
history of 773
Rapid communications 775
reviewers list 852
SI units and ..... 6(E), 79
Transfusion
and cancer recurrence 291
and immune modulation ..... 101(E), 188, 291, 644, 651
and metastases, animal model 188
and tumor stage 291
-associated deaths ..... 193(E), 207, 579(E), 583
effect 651
medicine
academic award program and NHLBI ..... 97(E)
blood donor motivation 444
education and
FFP usage 253
HCV 759
preoperative autologous blood donation 418
history of 358
informed consent doctrine 460
research opportunities in ..... 97(E)
use of PCR 51
physiology and transfusion trigger ..... 1(E), 11
practice
and NHLBI ..... 97(E)
antigen-matching of RBCs ..... 482(E), 532
autologous donation from bone marrow harvest 310
fetus ..... 76(L), 104, 168, 172, 175, 682
in ECMO ..... 289(E), 307
in PNH ..... 479(L)
individual components
FFP 253
FVIII, usage during shortage ..... 573(L)
platelets
in splenomegaly 508
single versus multiple donors ..... 219, 765(L)
UVB irradiation of 401
red cells
usage
at delivery 168, 172
in ECMO ..... 289(E), 307
in AIDS and ARC patients 133
in neonatal patients ..... 271, 289(E), 307, 565, 581(E), 599, 675(E), 764(L)
in pediatric patients ..... 68, 581(E), 599
in PNH ..... 470(L)
of limited-exposure donations 68
minimal-exposure ..... 581(E), 599
informed consent doctrine 460
minimal-exposure RBC ..... 581(E), 599
neonatal patients
ECMO ..... 289(E), 307
minimal-exposure ..... 581(E), 599
serologic testing 175
small-volume RBC 565
survey of practice 271
use of irradiated RBCs ..... 675(E), 764(L)
use of limited-exposure donations 68
pregnancy, serologic testing 175
reduction of TTD risk by
minmal-exposure transfusion 599
pharmacologic agents 541
prolonged storage of RBCs 851
washing of RBCs 851
safety of
blood bags, effects of plasticizers ..... 767(L)
blood supply ..... 4(E), 63, 97(E), 480(E)
use of CMV-negative blood products 659
use of preoperative autologous blood donation 418
reaction
anti-IgA-mediated 322
apheresis, removal of LDL cholesterol 327
bacterial contaminiation ..... 193(E), 207, 579(E), 583
death ..... 193(E), 207, 579(E), 583
delayed hemolytic 688
delayed serologic 688
donation of autologous blood 249
due to half-physiologic-strength saline as RBC diluent ..... 78(L)
febrile, nonhemolytic
role of WBC antibodies in 733
single versus multiple platelet donors and ..... 219, 765(L)
GVHD ..... 101(E)
nonhemolytic 30
risk after RBC transfusion 39
transfusion-related acute lung injury (TRALI) 42
WBC antibodies and 733
-transmitted disease (TTD)
bacteria, after room temperature exposure of RBCs 302
Borrelia burgdorferi 298
CMV ..... 528, 573(L), 659, 762, 808
fibrin glue 741
GVHD ..... 101(E), 849, 850
HCV ..... 374, 380(L), 471, 759
hepatitis B ..... 384(E), 431
HIV-1
reduction of risk ..... 191(L), 833, 851
utility of lookback procedures 214

HIV-2 184
HTLV-I/II 780, 783, 808
Lyme disease 298
non-A,non-B hepatitis 363, 368, 374
relapsing fever ..... 380(L)
syphilis ..... 773(E), 844
Yersinia enterocolitica ..... 193(E), 207, 579(E), 583
trigger, animal model ..... 1(E), 11
Transfusion Safety Study ..... 97(E), 851
Transplantation
bone marrow
donor registry, costs 138
in Chippewa Indians 728
large-volume harvest and autologous donation 310
of North American Indians 521, 728
risk of CMV in 659
standards for processing and storage ..... 571, 574(L)
unrelated, in ethnic and racial populations 521
in Fanconi anemia 682
solid-organ, risk of CMV in 659
PBSC, use of vena cava catheters 511
umbilical cord blood 682
Tri(n-butyl)phosphate (TNBP) and viral inactivation ..... 192(L), 591
Tumor
metastases and transfusion, animal model 188
stage and transfusion 291

U

Umbilical cord blood transplantion 682
Umbilical vein transfusions 104
Ultraviolet (UV) B irradiation
effect on WBCs in platelets 401
inactivation of viruses in blood products ..... 480(E)
of platelets 678
reduction of alloimmunization 401
use in cancer treatment ..... 288(L)
U.S. Food and Drug Administration (FDA) regulations ..... 4(E)
UVB irradiation, see ultraviolet irradiation

V

Variable number of tandem repeat region (VNTR), use in paternity testing 648
Varicella zoster virus ..... 478(L)
Vitamin K, pharmacology and use 541
Viral
inactivation of blood products
of FVIII 748
photosensitizers ..... 480(E), 485
solvent/detergent treatment ..... 192(L), 591
TNBP ..... 192(L), 591
ultraviolet light ..... 480(E)
infection in β-thalassemia 808
reduction by
filtration ..... 191(E), 833
freeze-thaw procedure 833
prolonged RBC storage 851
RBC washing 851
VNTR, see variable number of tandem repeat region
von Willebrand disease ..... 381(L), 541
VZV, see varicella zoster virus

W

Waterbath, prevention of bacterial contamination ..... 667(L)
Western blot, detection of HTLV-I/II 491
White cells (WBC)
and graft-versus-leukemia effect ..... 191(L)
antibodies in febrile, nonhemolytic transfusion reactions 733
-depleted components
and HIV transmission ..... 191(L), 833, 851
platelets ..... 34, 288(L), 718
quantitation of WBCs in ..... 117, 377, 387(E), 718
RBCs 26, 30
use in PNH ..... 479(L)
effect on platelets during storage 333
lymphocyte
reactivity and FN 791, 799
subpopulations in transfused patients 644
subsets in HTLV-I/II-positive donors 787
storage at microgravity 605
Whole blood and immune modulation 291

Y

Yersinia enterocolitica ..... 193(E), 207, 579(E), 583

Z

Zidovudine (AZT) and anemia in AIDS and ARC 133